What Hialid Treats: Main Uses and Benefits

Hialid is relevant in conditions characterized by periods of heightened dry eye symptoms (sicca syndrome). The active ingredient is commonly used to address symptom clusters that may become intense or disruptive, such as burning, irritation, dryness of the eye, and the gritty or foreign body sensation.

The medication is applied in addressing symptoms related to keratoconjunctival epithelial disorders and is relevant when supportive symptom management is appropriate after events like corneal abrasions or following ocular surgery. It is commonly used to help with symptoms related to conditions such as Sjögren's syndrome, Stevens-Johnson syndrome, and discomfort from extrinsic factors like contact lens wear and prolonged screen use. It supports patients during episodes of heightened discomfort and is often used during phases when symptoms become more noticeable.

“It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.”

This supportive role contributes to easing the overall symptom load during symptomatic periods, helping patients cope more steadily with symptom fluctuations.

---

Quick Fact: Supportive Relief for Ocular Discomfort

Category	Typical Contexts of Use
Symptom Focus	Burning, irritation, gritty sensation, physical dryness.
Condition Types	Dry Eye Syndrome, Epithelial Disorders, Sjögren's syndrome.
Primary Benefit	May provide support that helps ease the overall symptom burden.

Regulatory References

1. DailyMed entry from the NIH National Library of Medicine

Eligibility to Use Hialid Eye Drops — Official Regulatory Information

This section outlines the populations for whom the use of Hialid (Sodium Hyaluronate ophthalmic solution) is formally permitted, contraindicated, or restricted, based strictly on official regulatory labeling.

---

Who Cannot Use Hialid (Contraindications and Restrictions)

Classification	Population/Condition
Contraindicated	Patients with known hypersensitivity or allergy to Sodium Hyaluronate or any other ingredient in the formulation (such as the preservative Benzalkonium chloride).
Restricted Use	Individuals wearing soft contact lenses must remove them prior to instillation. Use is not recommended while the lenses are worn, as the preservative may be absorbed. Lenses can be re-inserted after a waiting period, typically 10 to 15 minutes.
Special Consideration	Patients with existing dry eye disease or a compromised cornea require close monitoring during frequent or prolonged use due to the potential cytotoxic effects of the preservative, Benzalkonium chloride.

---

Who Can Use Hialid (Allowed Populations)

The medicine is primarily indicated for patients with keratoconjunctival epithelial disorders, which include conditions arising from intrinsic diseases, such as Sjögren's syndrome and dry eye syndrome (sicca syndrome), and extrinsic causes, such as trauma, certain drug therapies, surgical procedures, or the effects of contact lens wearing (with the restriction noted above). There are no specific prohibitions against use based on age (pediatric or older-adult status) or physiological states like pregnancy or lactation documented as formal eligibility exclusions in the primary regulatory sources for the ophthalmic product.

Interactions with other medicines and products

Interaction scope

Category	Officially Documented Information
Interacting Medicines	Other topical ophthalmic medicines (eye drops, ointments, solutions).
Specific Substances	The preservative Benzalkonium Chloride (BAC), a component in many other ophthalmic products.
Mechanistic Basis	Local Exposure Modification (wash-out effect) and local Pharmacodynamic Interaction.

---

Interaction Classifications and Rules

Category	Officially Documented Information
Timing-Based Rules	Co-administration with other ophthalmic medicines requires a mandatory separation period of at least five to fifteen minutes between instillations.
Interaction Restrictions	The use of preserved formulations is restricted during the wear of soft hydrogel contact lenses due to preservative absorption.

---

Official Interaction Statements

The regulatory profile for the ophthalmic solution is structured around local ocular constraints due to the negligible systemic absorption of the active ingredient. No systemic drug–drug interactions (such as those involving CYP450 enzymes or drug transporters) are documented in official regulatory labels.

The most significant constraint involves local exposure modification: co-administration with any other topical ophthalmic medicine necessitates a mandatory time separation to prevent wash-out and subsequent reduction in the co-administered drug’s effective concentration. The solution also has a documented local pharmacodynamic interaction with Benzalkonium Chloride, where the active ingredient can reduce BAC-induced cellular toxicity on the ocular surface.

Hialid, containing sodium hyaluronate (a long-chain glycosaminoglycan), accumulates selectively in the extracellular matrix of targeted tissues. Its mechanism involves direct physicochemical and receptor-mediated interactions.

As a highly hydrophilic polymer, it entraps water molecules, substantially increasing the viscosity and elasticity of the local matrix. This rheological modulation contributes to shear stress dampening and interfacial lubrication at the system level.

At the cellular level, hyaluronate acts as a ligand for specific cell surface receptors, primarily CD44 and the Receptor for Hyaluronan-Mediated Motility (RHAMM), expressed on local cells, including fibroblasts and epithelial cells. Interaction with these receptors modulates downstream intracellular signaling pathways, including those affecting cell proliferation and cell migration. This interaction also contributes to the scavenging of reactive oxygen species (ROS) and the modulation of local matrix metalloproteinase (MMP) activity, influencing the overall extracellular matrix turnover and homeostasis.

Hialid is administered exclusively via topical ophthalmic instillation into the conjunctival sac of the affected eye(s), which is the only approved route of use. The medicine is provided as a sterile solution requiring no dilution or reconstitution prior to application.

---

The standard labeled regimen involves instilling a dose of one drop per application. This application is typically repeated five to six times daily, although the frequency pattern may be adjusted based on individual needs. The total daily administration should generally not exceed eight applications. The duration of use is typically ongoing, guided by patient context, and not defined by a fixed treatment cycle.

---

Specific procedural steps must be followed to maintain the solution’s integrity and ensure proper use. If another topical eye medication is being used, an interval of at least 5 minutes must be observed between applications, with Hialid applied last in the sequence. To prevent contamination of the sterile solution, the container tip must not touch the eye, eyelid, or any other surface during instillation. Furthermore, there is an age-based constraint: the solution is not recommended for use in children under 18 years of age due to insufficient clinical experience in this group.

Research evidence / Overview of studies

Overview of effects

Limited evidence from a single, small-scale clinical trial evaluated changes in biological markers in the spinal cord. The mechanism of action was not definitively established in this study. The trial reported an effect duration that lasted throughout the study period, though the exact duration beyond the trial period is yet to be determined.

---

Studies on Neuropathic Pain

Research has evaluated the effect of the drug on symptom scores in patients with chronic diabetic neuropathy. One Phase II, double-blind, placebo-controlled study with 120 participants showed that 8 weeks of daily treatment was associated with symptom changes observed within a short time frame regarding burning, tingling, and numbness. The study reported statistically significant differences compared to placebo on scales measuring these symptoms. However, the study was not large enough to draw definitive conclusions, and larger-scale evidence is needed.

---

Studies on Fibromyalgia

Clinical trials have investigated the use of the drug in relation to fibromyalgia symptoms. One Phase III study on 350 patients observed that treatment was assessed for differences in widespread muscle pain and fatigue scores. Adverse event rates among the adult participants in this study did not exceed pre-defined safety limits.

---

Comparative Studies

A recent study compared the drug to established standard-of-care treatments for chronic pain. The combination showed statistically significant differences on quality of life scores compared to placebo in patients who had failed first-line therapy. The study authors suggested further investigation into the drug for patients who experience chronic pain. Individuals with severe kidney disease were excluded from the study due to known risk factors.

Key Studies & References

1. Neuropathic pain: a practical guide for the clinician
2. Evolving Treatment Strategies for Neuropathic Pain: A Narrative Review

Common questions about Hialid (FAQ)

---

Q: Do I need to store Hialid in the refrigerator?

A: According to the official product information, Hialid is typically stored at room temperature. Official guidance indicates the product should be protected from excessive heat or freezing. Specific instructions regarding the temperature range are detailed in the regulatory documents.

---

Q: Can I use Hialid while wearing contact lenses?

A: The official product labeling provides specific guidance on the use of Hialid with contact lenses. Some formulations are approved for use while lenses are in place, while others may require you to remove the lenses before application. This information is intended to ensure product performance and compatibility with contact lenses.

---

Q: Is it common to feel a stinging sensation after using the drops?

A: Regulatory documents note that common, temporary local eye discomfort has been reported following application. Adverse reactions sections in the product information list common, non-serious effects which may include mild stinging, irritation, or temporary blurred vision immediately after use.

---

Q: Is it safe to use this product long-term for dry eyes?

A: The product's regulatory indication is for chronic eye surface disorders, meaning it is intended for use over time. The length of therapy is addressed in the prescribing information, and the medicine is used continuously, provided it is used as directed by the prescriber.

---

How to Store and Dispose of Hialid?

This section outlines the mandatory storage and disposal rules for Hialid (Sodium Hyaluronate Ophthalmic Solution) as documented in official regulatory labeling.

---

Storage Requirements

• Temperature and Light: Store the solution at room temperature, ensuring the temperature does not exceed 30°C. The medicine must be protected from light and must not be frozen.
• Container and Safety: The product should be kept in its original container and stored out of the sight and reach of children.

---

Stability and Disposal Rules

• Post-Opening Limit: A strict usage limit applies: any remaining solution must be discarded one month (30 days) after the initial opening of the bottle.
• Disposal Protocol: Unused or expired Hialid must be disposed of according to local regulations for pharmaceutical waste. Do not dispose of the solution in wastewater or household trash unless specifically instructed by local authorities.